Dyspnea, commonly known as breathlessness, is a frequent clinical presentation in both inpatient and outpatient settings. The etiology of dyspnea is multifactorial, often making diagnosis and management challenging. This article aims to provide a comprehensive clinical approach to dyspnea.
Dyspnea may be the result of cardiac, respiratory, neuromuscular, psychogenic, or metabolic disorders. A detailed history and physical examination are crucial initial steps. These should focus on the onset, duration, and exacerbating or relieving factors of the breathlessness. Associated symptoms such as cough, chest pain, and orthopnea can provide clues to the underlying cause.
Diagnostic evaluation should be guided by the clinical suspicion. Basic investigations include complete blood count, chest X-ray, and electrocardiogram. Pulmonary function tests can assess the degree of airflow obstruction. If cardiac etiology is suspected, echocardiography and cardiac stress tests may be warranted. In uncertain cases, CT scan or bronchoscopy may be necessary.
The management of dyspnea should be directed towards the underlying cause. For instance, in patients with COPD, bronchodilators and steroids may be beneficial. Patients with heart failure may require diuretics, beta-blockers, and ACE inhibitors. Non-pharmacological interventions such as pulmonary rehabilitation and breathing exercises can also be beneficial. In palliative care settings, opioids may be used to alleviate breathlessness.
Understanding the multifactorial nature of dyspnea is key to its effective management. A systematic approach, including detailed history, physical examination, and appropriate investigations, can help identify the underlying cause. Tailored management strategies can then be implemented to provide symptomatic relief and improve quality of life. Continued research is needed to further refine our understanding and approach to the breathless patient.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation